Assistive AI in Lung Cancer Screening: A Retrospective Multinational Study in the United States and Japan.

IF 8.1 Q1 COMPUTER SCIENCE, ARTIFICIAL INTELLIGENCE
Atilla P Kiraly, Corbin A Cunningham, Ryan Najafi, Zaid Nabulsi, Jie Yang, Charles Lau, Joseph R Ledsam, Wenxing Ye, Diego Ardila, Scott M McKinney, Rory Pilgrim, Yun Liu, Hiroaki Saito, Yasuteru Shimamura, Mozziyar Etemadi, David Melnick, Sunny Jansen, Greg S Corrado, Lily Peng, Daniel Tse, Shravya Shetty, Shruthi Prabhakara, David P Naidich, Neeral Beladia, Krish Eswaran
{"title":"Assistive AI in Lung Cancer Screening: A Retrospective Multinational Study in the United States and Japan.","authors":"Atilla P Kiraly, Corbin A Cunningham, Ryan Najafi, Zaid Nabulsi, Jie Yang, Charles Lau, Joseph R Ledsam, Wenxing Ye, Diego Ardila, Scott M McKinney, Rory Pilgrim, Yun Liu, Hiroaki Saito, Yasuteru Shimamura, Mozziyar Etemadi, David Melnick, Sunny Jansen, Greg S Corrado, Lily Peng, Daniel Tse, Shravya Shetty, Shruthi Prabhakara, David P Naidich, Neeral Beladia, Krish Eswaran","doi":"10.1148/ryai.230079","DOIUrl":null,"url":null,"abstract":"<p><p>Purpose To evaluate the impact of an artificial intelligence (AI) assistant for lung cancer screening on multinational clinical workflows. Materials and Methods An AI assistant for lung cancer screening was evaluated on two retrospective randomized multireader multicase studies where 627 (141 cancer-positive cases) low-dose chest CT cases were each read twice (with and without AI assistance) by experienced thoracic radiologists (six U.S.-based or six Japan-based radiologists), resulting in a total of 7524 interpretations. Positive cases were defined as those within 2 years before a pathology-confirmed lung cancer diagnosis. Negative cases were defined as those without any subsequent cancer diagnosis for at least 2 years and were enriched for a spectrum of diverse nodules. The studies measured the readers' level of suspicion (on a 0-100 scale), country-specific screening system scoring categories, and management recommendations. Evaluation metrics included the area under the receiver operating characteristic curve (AUC) for level of suspicion and sensitivity and specificity of recall recommendations. Results With AI assistance, the radiologists' AUC increased by 0.023 (0.70 to 0.72; <i>P</i> = .02) for the U.S. study and by 0.023 (0.93 to 0.96; <i>P</i> = .18) for the Japan study. Scoring system specificity for actionable findings increased 5.5% (57% to 63%; <i>P</i> < .001) for the U.S. study and 6.7% (23% to 30%; <i>P</i> < .001) for the Japan study. There was no evidence of a difference in corresponding sensitivity between unassisted and AI-assisted reads for the U.S. (67.3% to 67.5%; <i>P</i> = .88) and Japan (98% to 100%; <i>P</i> > .99) studies. Corresponding stand-alone AI AUC system performance was 0.75 (95% CI: 0.70, 0.81) and 0.88 (95% CI: 0.78, 0.97) for the U.S.- and Japan-based datasets, respectively. Conclusion The concurrent AI interface improved lung cancer screening specificity in both U.S.- and Japan-based reader studies, meriting further study in additional international screening environments. <b>Keywords:</b> Assistive Artificial Intelligence, Lung Cancer Screening, CT <i>Supplemental material is available for this article.</i> Published under a CC BY 4.0 license.</p>","PeriodicalId":29787,"journal":{"name":"Radiology-Artificial Intelligence","volume":" ","pages":"e230079"},"PeriodicalIF":8.1000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11140517/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiology-Artificial Intelligence","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1148/ryai.230079","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"COMPUTER SCIENCE, ARTIFICIAL INTELLIGENCE","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose To evaluate the impact of an artificial intelligence (AI) assistant for lung cancer screening on multinational clinical workflows. Materials and Methods An AI assistant for lung cancer screening was evaluated on two retrospective randomized multireader multicase studies where 627 (141 cancer-positive cases) low-dose chest CT cases were each read twice (with and without AI assistance) by experienced thoracic radiologists (six U.S.-based or six Japan-based radiologists), resulting in a total of 7524 interpretations. Positive cases were defined as those within 2 years before a pathology-confirmed lung cancer diagnosis. Negative cases were defined as those without any subsequent cancer diagnosis for at least 2 years and were enriched for a spectrum of diverse nodules. The studies measured the readers' level of suspicion (on a 0-100 scale), country-specific screening system scoring categories, and management recommendations. Evaluation metrics included the area under the receiver operating characteristic curve (AUC) for level of suspicion and sensitivity and specificity of recall recommendations. Results With AI assistance, the radiologists' AUC increased by 0.023 (0.70 to 0.72; P = .02) for the U.S. study and by 0.023 (0.93 to 0.96; P = .18) for the Japan study. Scoring system specificity for actionable findings increased 5.5% (57% to 63%; P < .001) for the U.S. study and 6.7% (23% to 30%; P < .001) for the Japan study. There was no evidence of a difference in corresponding sensitivity between unassisted and AI-assisted reads for the U.S. (67.3% to 67.5%; P = .88) and Japan (98% to 100%; P > .99) studies. Corresponding stand-alone AI AUC system performance was 0.75 (95% CI: 0.70, 0.81) and 0.88 (95% CI: 0.78, 0.97) for the U.S.- and Japan-based datasets, respectively. Conclusion The concurrent AI interface improved lung cancer screening specificity in both U.S.- and Japan-based reader studies, meriting further study in additional international screening environments. Keywords: Assistive Artificial Intelligence, Lung Cancer Screening, CT Supplemental material is available for this article. Published under a CC BY 4.0 license.

肺癌筛查中的辅助人工智能:美国和日本的一项多国回顾性研究。
"刚刚接受 "的论文经过同行评审,已被接受在《放射学》上发表:人工智能》上发表。这篇文章在以最终版本发表之前,还将经过校对、排版和校对审核。请注意,在制作最终校对稿的过程中,可能会发现影响文章内容的错误。目的 评估肺癌筛查人工智能(AI)助手对跨国临床工作流程的影响。材料与方法 在两项回顾性随机多机多病例研究中对肺癌筛查人工智能助手进行了评估,由经验丰富的胸部放射科医生(6 位美国医生或 6 位日本医生)对 627 例(141 例癌症阳性)低剂量胸部 CT 病例分别进行了两次解读(有人工智能助手和无人工智能助手),共得出 7524 个解读结果。阳性病例定义为病理确诊肺癌前两年内的病例。阴性病例是指至少两年内没有任何后续癌症诊断的病例,并包含各种不同的结节。这些研究衡量了读者的怀疑程度(LoS,0-100 分)、特定国家筛查系统评分类别和管理建议。评估指标包括 LoS 的接收者操作特征曲线下面积(AUC)以及召回建议的灵敏度和特异性。结果 在人工智能的协助下,美国研究中放射科医生的 AUC 增加了 0.023(0.70 至 0.72,P = .02),日本研究中增加了 0.023(0.93 至 0.96,P = .18)。在美国研究中,评分系统对可操作结果的特异性提高了 5.5%(57%-63%,P < .001),在日本研究中提高了 6.7%(23%-30%,P < .001)。在美国(67.3%-67.5%,P = .88)和日本(98%-100%,P > .99)的研究中,没有证据表明无辅助读取和人工智能辅助读取的相应灵敏度存在差异。美国和日本数据集的相应独立人工智能 AUC 系统性能分别为 0.75 95%CI [0.70-0.81] 和 0.88 95%CI [0.78-0.97]。结论 同步人工智能界面提高了美国和日本读者研究中的 LCS 特异性,值得在其他国际筛查环境中进一步研究。©RSNA,2024。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
16.20
自引率
1.00%
发文量
0
期刊介绍: Radiology: Artificial Intelligence is a bi-monthly publication that focuses on the emerging applications of machine learning and artificial intelligence in the field of imaging across various disciplines. This journal is available online and accepts multiple manuscript types, including Original Research, Technical Developments, Data Resources, Review articles, Editorials, Letters to the Editor and Replies, Special Reports, and AI in Brief.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信